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Abstract 
Background: Filovirus virus-like particles (VLP) are strong immunogens with the potential for development into 
a safe, non-infectious vaccine. However, the large size and filamentous structure of this virus has heretofore made 
production of such a vaccine difficult. Herein, we present new assays and a purification procedure to yield a better 
characterized and more stable product.
Methods: Sonication of VLP was used to produce smaller “nano-VLP”, which were purified by membrane chroma-
tography. The sizes and lengths of VLP particles were analyzed using electron microscopy and an assay based on 
transient occlusion of a nanopore. Using conformationally-sensitive antibodies, we developed an in vitro assay for 
measuring GP conformational integrity in the context of VLP, and used it to profile thermal stability.
Results: We developed a new procedure for rapid isolation of Ebola VLP using membrane chromatography that 
yields a filterable and immunogenic product. Disruption of VLP filaments by sonication followed by filtration pro-
duced smaller particles of more uniform size, having a mean diameter close to 230 nm. These reduced-size VLP 
retained GP conformation and were protective against mouse-adapted Ebola challenge in mice. The “nano-VLP” 
consists of GP-coated particles in a mixture of morphologies including circular, branched, “6”-shaped, and filamentous 
ones up to ~1,500 nm in length. Lyophilization conferred a high level of thermostability on the nano-VLP. Unlike Ebola 
VLP in solution, which underwent denaturation of GP upon moderate heating, the lyophilized nano-VLP can with-
stand at least 1 h at 75°C, while retaining conformational integrity of GP and the ability to confer protective immunity 
in a mouse model.
Conclusions: We showed that Ebola virus-like particles can be reduced in size to a more amenable range for manip-
ulation, and that these smaller particles retained their temperature stability, the structure of the GP antigen, and the 
ability to stimulate a protective immune response in mice. We developed a new purification scheme for “nano-VLP” 
that is more easily scaled up and filterable. The product could also be made thermostable by lyophilization, which is 
highly significant for vaccines used in tropical countries without a reliable “cold-chain” of refrigeration.
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Background
The filoviruses Ebola and Marburg are enveloped 
viruses causing lethal, hemorrhagic disease in humans 
and non-human primates [1]. The virions exist in a 
mixture of morphologies, including “6”-shaped and 
filamentous particles. The filaments are 80–100  nm in 
width and can be several microns long [2]. The sur-
face of the virions is covered in trimeric spikes of the 
glycoprotein (GP), while the VP40 protein forms a 
structural matrix underlying the viral membrane. For-
mation of virus-like particles (VLP) with shapes similar 
to authentic filoviruses can be induced by transfection 
into human or insect cell lines of the genes for GP and 
VP40 alone [3–6]. The five other viral proteins are not 
essential for production of virus-like particles, although 
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some efforts have also included the nucleocapsid pro-
tein NP.
VLP are useful as laboratory reagents for the explora-
tion of filovirus biology, and they are promising candi-
dates for vaccines to protect humans against natural or 
deliberate exposure to these viruses [7]. Non-human pri-
mates have been successfully immunized against Ebola 
with VLP plus adjuvant, with at least two doses needed 
for full protection, while one conferred partial protec-
tion [8, 9]. Filovirus VLP are more effective than solu-
ble GP proteins at stimulating the immune system [10]. 
The presentation of GP trimers in a repetitive array likely 
contributes to their potency by increasing interactions 
with receptors on B cells and antigen-presenting cells [2, 
11]. However, unlike VLP of some other types of viruses, 
which may consist only of smaller, spherical and non-
enveloped proteinaceous particles that can be reassem-
bled in  vitro from isolated subunits, filovirus VLP can 
be several microns in length and are enveloped. These 
characteristics present difficult problems in purification, 
sterilization and analytical methods. Development of the 
filovirus VLP as vaccines for humans hence has been lim-
ited by the methods used in production, which rely upon 
sucrose gradient ultracentrifugation for purification and 
gamma-irradiation for sterilization. Production of the 
VLP by transient transfection also introduces high costs 
to supply the doses used in NHP experiments (typically 
50–250 µg GP), therefore more efficient means of expres-
sion are desirable.
The influence of the large size of the filaments on 
stimulation of the immune response is not yet clear. The 
optimal size and shape of nanoparticle vaccines is an 
important factor in their design and a subject of current 
interest (reviewed in [12–14]). For example, Manolova 
et  al. [15] studied the effect of particle size on antigen 
uptake by dendritic cells and found that polystyrene 
beads of ≤200  nm were able to drain rapidly to lymph 
nodes, where they were taken up by lymph node-resident 
dendritic cells and macrophages. Beads ≥500  nm could 
not directly enter the lymphatic system, and were taken 
up more slowly by a different population of dendritic cells 
at the site of injection. Champion and Mitragotri [16] 
found that worm-like polystyrene particles were taken up 
by macrophages very poorly when compared to spheri-
cal particles. These results suggest that it may be advan-
tageous to the immune response to reduce the length of 
filovirus VLP.
In this study, we examined how changes in particle 
size and GP conformation affect immunogenicity using 
a combination of mouse bioassays, electron microscopy 
(EM), antibody-based probes of GP, and a nanopore siz-
ing method. We also demonstrate a rapid in vitro test for 
antigenic integrity that was correlated to in vivo potency, 
and confirm the functional significance of conformation-
ally intact GP for the vaccine. We present results describ-
ing a new version of the Ebola VLP vaccine consisting of 
smaller particles that are more easily purified and can be 
filtered to reduce bioburden.
Methods
VLP production and purification
VLPs were produced at NCI and USAMRIID using a 
modification of the procedure described by Warfield 
et al. [3]. In brief, VLPs were created by transfecting HEK 
293 cells with expression vectors containing the genes 
for GP and VP40 proteins. After a low-speed centrifuga-
tion to remove cells, VLP in the culture supernatant were 
centrifuged to a pellet using a Beckman JLA10.5 rotor at 
10,000 rpm (~18,500×g). The pellet was resuspended in 
PBS and applied to a 10–60% sucrose gradient. The gradi-
ent was then spun at 174,000×g for 14  h. The resulting 
band was removed from the gradient and washed twice in 
sterile PBS. The VLP were resuspended in PBS and stored 
at 4°C, to be used in freeze/thaw studies. VLP were also 
produced under a contract at Paragon Bioservices, using 
a sucrose-gradient based method performed at a larger 
scale with a Wave bioreactor and HEK 293F suspension 
cells. These samples were stored frozen at −80°C.
The concentration of GP in the VLP was determined at 
Paragon by quantitative Western blotting with antibody 
6D8, using recombinant soluble GP protein with a C-ter-
minal His-tag in place of the transmembrane peptide as 
the standard. Subsequent measurement of GP concentra-
tions of VLP samples were done by ELISA at USAMRIID 
and gave results within 10% of those found by Western 
blotting. GP was typically 20–30% of the total protein 
as measured by bicinchoninic acid assay. To measure 
GP concentration by ELISA, a standard curve was pre-
pared by adhering recombinant soluble GP protein over-
night to an ELISA plate (Immulon 2HB from Thermo 
Fisher #3455) in carbonate buffer at pH 9.5 (Additional 
file 1: Figure S1). The soluble GP protein was expressed 
in HEK293 c18 cells, and had the transmembrane region 
replaced by a His-tag for purification. It was quanti-
tated by UV absorbance (A280 1 mg/mL = 1.30). GP on 
the ELISA plate was detected by probing with antibody 
6D8 and an HRP-conjugated goat anti-mouse second-
ary antibody (Thermo Fisher #31430). The absorbance at 
408 nm was fit to a 4-parameter logistic equation using 
SigmaPlot.
Sonication and filtration
Sonication of VLP was done using a Branson Sonifier 250 
with a 1/8 inch tapered microtip. To prepare VLP sam-
ples for further study, 0.5 mL of VLP in PBS were soni-
cated for 3 sets of 3 pulses of 1  s duration, at 50% duty 
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cycle with the output control at 5.5. Samples were chilled 
on ice after each set of pulses.
Filtration was done by passage through a 2.5 cm Supor 
syringe filter (Pall) of either 0.45 µm or 0.8/0.2 µm pore 
size.
Electron microscopy
Samples of VLP were adsorbed to formvar/carbon coated 
grids for electron microscopy and stained with PTA 
(phosphotungstic acid) or uranyl acetate. Samples were 
evaluated on a JEOL 1011 transmission electron micro-
scope at 80 kV and digital images were acquired using an 
Advanced Microscopy Techniques (Danvers, MA, USA) 
digital camera system.
Particle sizing
The particle size distribution of the samples was meas-
ured using an IZON qViro scanning ion occlusion sens-
ing device. An IZON NP200A pore (nominal 200  nm 
diameter) was used, which was stretched until particles 
flowed freely. The voltage was 0.3–0.4 V and the pressure 
was varied up to 1.5 kPa. The sample introduced into the 
upper chamber contained 40 µL of VLP with 0.4–0.8 µg/
mL [GP]. The buffer was PBS with 50 µg/mL Tween-80. 
Between 800 and 1,500 data points were collected for 
each experiment. The calibration standard was 217  nm 
polystyrene beads (SKP200B) diluted to 1  ×  109 parti-
cles/mL concentration.
Particle concentrations were determined from the pres-
sure dependence of the event rate [17]. The concentration 
of an unknown sample (C2) was found from the slope of 
the pressure dependence of the sample’s event rate (g2), 
the calibration standard’s slope (g1), and the concentra-
tion of the standard (C1):
Conformational ELISA
VLP samples were diluted in 0.2  M sodium carbonate/
bicarbonate buffer at pH 9.5 for coating of an Immulon 
2HB plate (Thermo Fisher) overnight at 4°C. After wash-
ing four times with PBS/0.05% Tween-20, plates were 
blocked with 3% dry milk in PBS for 1.5  h at 37°C. The 
wells were probed with antibody 6D8, 6D3, or 13C6 in 02% 
casein/PBS. 6D8 was used at 2.5 µg/mL, 6D3 at 1 µg/mL, 
and 13C6 at 1.6 µg/mL. HRP-labeled goat anti-mouse-Fc 
(Thermo) was the secondary antibody. Plates were devel-
oped with an ABTS peroxidase substrate (KPL), stopped 
with 1% SDS, and the absorbance read at 408 nm.
Nano‑VLP purification
Transfection of HEK 293 c18 cells (ATCC CRL-10852) 







was done using PEI as transfectant and 500  mL shaker 
flask cultures. After 3 days growth, the culture was cen-
trifuged to remove cells (1773×g for 15 min). The super-
natant was then centrifuged at higher speed to pellet the 
VLP (18.6K×g for 2 h). The pellet from each liter of cells 
was resuspended in 10 mL of 10 mM sodium phosphate, 
50  mM NaCl, pH 7.4 (buffer 1), and kept on ice. The 
resuspended pellet was sonicated to increase the fluid-
ity of the sample and decrease the length of filamentous 
VLP, allowing for more efficient filtration.
Sonication of VLP was done using a Branson Sonifier 
250 as described above. 10–12  mL of crude VLP in a 
50 mL conical tube were sonicated for 4 sets of 3 pulses 
of 1  s duration, at 50% duty cycle with the output con-
trol at 5.5. Samples were chilled on ice after each set of 
pulses. After sonication, samples were diluted with an 
equal volume of buffer 1. The sample was then filtered 
once through a 2.5  cm GF/D filter (Whatman glass 
microfiber), and then twice through GF/F filters. These 
steps removed a quantity of yellow colloidal material. 
20 mL of the filtered sample was then run over a Sarto-
rius Sartobind S-75 membrane chromatography disc, 
pre-equilibrated with buffer 1 on a GE Healthcare FPLC 
system. The VLP flowed through the S-75 disc. Bound 
contaminants were eluted for analysis only using a gradi-
ent to 2 M NaCl. The flow rate was 1 mL/min at a back-
pressure of 0.16 MPa. S-75 discs were not reused.
The flow-through of the S-75 disc was again sonicated 
for 3 sets of 3 pulses to reduce particle size. The sam-
ple was then centrifuged in 50 mL conical tubes for 2 h 
at 14.6K×g) in a swinging bucket rotor. The pellet was 
resuspended in 2 mL of a sterile 0.5× PBS solution with 
5% trehalose. The final filtration step to remove aggre-
gates was done with a 2.5  cm Pall 0.45 µM Supor filter. 
Bioburden was tested by plating on LB agar at 37°C and 
no growth was found. Use of a 0.2 µM filter caused addi-
tional loss of the VLP and was not necessary to remove 
microbes for laboratory reagent purposes. Samples were 
then either stored frozen at −80°C, or lyophilized. Sam-
ples for SDS-PAGE were reduced and heated before load-
ing on NuPage 4–12% Bis–Tris gels (Life Technologies).
Lyophilization
For lyophilization, 262  µL volume samples in 0.5× 
PBS  +  5% trehalose containing 60  µg GP each were 
placed in 2  mL glass vials. 5% trehalose was included 
in the buffer as a protectant against stresses associated 
with freezing and dehydration. The samples were fro-
zen on dry ice, and then placed on the shelf of a VirTis 
AdVantage ES freeze-dryer at −20°C for drying in one 
stage. After 24 h exposure to vacuum (80 MT), the sam-
ples were reduced to a white powder. For stress-testing, 
the stoppered glass vial containing lyophilized VLP was 
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placed in a 75°C block for 1 h. A 26G needle was inserted 
to vent the cap during heating. All samples were resus-
pended in sterile water at the time of use.
In vivo efficacy
VLP were diluted in sterile saline for intramuscular 
administration. When the adjuvant poly-ICLC was 
used, it was diluted with the VLP in sterile saline and 
co-administered. Lyophilized VLP were reconstituted 
to approximately 500  µg/ml in sterile water prior to 
dilution in sterile saline. For all vaccination studies, 
female C57BL/6 mice (age 8–10 weeks) were vaccinated 
intramuscularly two times with 100 µl of volume, with 
3 weeks between vaccinations. Two weeks after the final 
vaccination, peripheral blood was collected from vacci-
nated mice and antibody titers were measured using an 
IgG ELISA. Four weeks after the final vaccination, mice 
were challenged via the intraperitoneal (IP) route with 
1,000 pfu of mouse adapted (ma)-EBOV [18]. Research 
was conducted under an IACUC approved protocol in 
compliance with the Animal Welfare Act, PHS Policy, 
and other Federal statutes and regulations relating to 
animals and experiments involving animals. The facil-
ity where this research was conducted, USAMRIID, 
is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International, 
and it adheres to principles stated in the 8th Edition of 
the Guide for the Care and Use of Laboratory Animals, 
National Research Council, 2011.
Anti‑glycoprotein ELISA
Anti-glycoprotein antibody titers were determined by 
ELISA. 2 µg/mL of recombinant Ebola virus glycoprotein 
was incubated in a flat bottom 96 well plate overnight. 
Glycoprotein with a C-terminal His-tag and lacking the 
transmembrane was expressed in HEK 293 c18 cells and 
purified by IMAC. Plates were incubated with block-
ing buffer (5% milk, 0.05% Tween in PBS) for 2  h, and 
then serum samples were added to plates. Samples were 
diluted by half log dilutions ranging from 2 to 5.5 logs. 
After 2 h, plates were washed with PBS + 0.05% Tween 
and goat anti-mouse IgG-HRP secondary antibody was 
added at a 0.6 µg/mL. One hour later, plates were washed 
and exposed using Sure Blue TMB 1-component sub-
strate and stop solution (KPL), and the absorbance at 
450 nm was recorded. Serum from unvaccinated animals 
was used to establish background and titers were defined 
as the serum dilution resulting in an absorbance greater 
than 0.2, where background was universally less than 0.2. 
Serum from animals previously determined to contain 
anti-glycoprotein antibody was included in each assay to 
serve as a positive control.
Results
Impact of sonication and filtration on the size distribution 
of VLP
As seen in earlier analyses [19], electron microscopy 
revealed that the Ebola Zaire VLP samples contained 
long filaments (>1 μm) with bulbous regions that resem-
ble Ebola virions, spherical particles similar to the head 
region of the virus, and some large irregular objects that 
might be cellular debris (Figure  1a). Sonication of the 
VLP was optimized by varying the number of applied 
pulses until conditions were found that yielded frag-
ments of up to ~400 nm length (Figure 1b) Sonication for 
a total of nine pulses was adequate to fragment the VLP, 
Figure 1 Electron micrographs of VLP before and after sonication. Bar is 0.5 µm. a Intact VLP. b Sonicated VLP.
Page 5 of 14Carra et al. J Transl Med  (2015) 13:228 
but more extensive disruption for a total of 30 pulses 
resulted in substantial loss of the integrity of the VLP 
membrane. Filtration of the sonicated samples through 
either a 0.45 µm or 0.8/0.2 µm cutoff syringe filter yielded 
both spherical particles and fragments of filaments, and 
effectively removed the larger particles and aggregates. 
Sonication of VLP improved the yield of GP through a 
0.8/0.2 μm filter from 10 to 50%, and through a 0.45 μm 
filter from 28 to 63%.
The size distribution of the VLP samples was ana-
lyzed by Scanning Ion Occlusion Sensing (SIOS). In 
this method, particles in the sample are forced through 
a pore of adjustable size by an applied pressure and an 
electroosmotic potential. As particles pass through the 
pore, a change in current due to pore blockage is meas-
ured as a function of time. The amplitude of the decrease 
in current is proportional to the degree to which the 
pore is blocked, while the duration of the blockade event 
is the time required for the particle to transit the pore. 
One advantage of this method lies in the characterization 
of heterogeneous samples containing particles of differ-
ent sizes and shapes, which may be detected as individ-
ual blockade events rather than averaged over the whole 
population.
SIOS analysis of the undisrupted VLP yielded a bifur-
cated plot of the blockade event duration in ms (FWHM: 
full width at half maximum) vs. blockade height in nA 
(Figure  2a). The events of lesser height and longer dura-
tion in the VLP sample are consistent with the transit of 
narrow, elongated filamentous particles through the pore. 
VLP filaments, which are 70–85 nm wide and up to 4 µm 
in length, may be expected to block the pore only partially, 
while taking a relatively long period of time to transit. In 
comparison, the spherical 217 nm polystyrene beads used 
for calibration showed a tight cluster of blockade events 
of less than 2 nA magnitude and 0.2 ms duration. Disrup-
tion of the VLP by sonication (Table 1) resulted in the loss 
of most events with greater blockade amplitudes (>2 nA) 
Figure 2 Nanopore measurements. a Intact VLP (green) sonicated VLP (blue) and 217 nm polystyrene beads (pink). b VLP after sonication and pas-
sage through a 0.45 µm (red) or 0.8/0.2 µm (cyan) filter. c The calculated particle size distribution of filtered VLP samples after calibration using the 
polystyrene beads. d Pressure dependence of the particle flow rate. Calibration beads (green triangles), sonicated and filtered (0.45 μm) VLP (blue 
circles). R2 was 0.99 for both linear regressions.
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and nearly all those of longer duration (>0.2 ms), consist-
ent with the disruption of filaments observed in the EM. 
Passage of the sonicated VLP through a 0.8/0.2 μm syringe 
filter removed the larger remaining particles (Figure 2b).
Figure  2c shows the calculated particle size distribu-
tions of the filtered samples, which were consistent with 
what was observed by EM. The mean particle size is nor-
mally calculated from SIOS data by calibration using 
beads of known size [20]. However, this analysis may not 
be appropriate when the sample contains a significant 
fraction of elongated, non-spherical particles. We there-
fore present mean particle sizes only for the sonicated 
samples (Table 1), which have a relatively narrow distri-
bution of particle sizes and shapes. The smaller particles 
of less than 150 nm could not be simultaneously resolved 
in this nanopore measurement; however we have chosen 
to focus the particles >150  nm that were identifiable as 
VLP or fragments of VLP.
SIOS can also be used to determine particle concen-
trations from the rate of observed events compared to a 
calibration standard of known concentration [17]. How-
ever, passage of intact VLP samples through the SIOS 
pore was frequently interrupted by blockages, presum-
ably due to the larger aggregates present. These blockages 
did not affect the particle size measurements, which were 
determined from individual events. Experiments could 
be resumed by pipetting the sample up and down, but a 
consistent flow rate of particles through the pore could 
not be obtained. By removal of larger particles or aggre-
gates from the sample, filtration allowed a smooth flow 
through the pore for more than 1 min.
Measurement of the rate of events at various applied 
pressures (Figure 2d) was then done to allow calculation 
of the particle concentration from the relative slopes of 
the pressure dependence curves. For the filtered VLP 
sample shown, the concentration was 8.2  ±  0.8  ×  1011 
particles/mL (±SE, n = 3).
Thermostability of GP in VLP
GP only comprises approximately 20–30% of the total 
protein in VLP preparations, but it is the most significant 
component in terms of immunogenicity [6]. The confor-
mational integrity of GP is hypothesized to be important 
for immunogenicity. We therefore sought to develop an 
ELISA method that would characterize specifically the 
conformation of GP in VLP preparations subjected to 
applied stress. In this approach, we compared the relative 
amount of binding of antibodies that recognize either 
linear or conformational epitopes. Denaturation of GP 
would be expected to result in loss of recognition by the 
conformationally-sensitive antibodies, while binding of 
the linear epitope antibody would be maintained.
Antibody 6D8 recognizes a linear epitope of GP (a.a. 
389–405), while 13C6 and 6D3 are conformationally-
dependent [21, 22]. 13C6 is known to bind to the glycan 
cap [23]. All are non-competing. We anticipated that 
if GP were denatured by applied stress, binding by 6D8 
should remain relatively constant, while binding by 6D3 
and 13C6 should decrease.
We used the ELISA method to test the resistance of 
both untreated, filamentous VLP and sonicated VLP to 
accelerated degradation by thermal stress. VLP samples 
were incubated at elevated temperatures for the indicated 
time periods in Figure 3a, b. Under all conditions tested, 
there was no difference between the impacts of thermal 
stress on sonicated VLP as compared to intact VLP, indi-
cating that fragmentation of the VLP did not affect the 
conformational stability of GP.
Incubation at 37°C for up to 96  h had no significant 
effect on the conformational integrity of GP, as judged by 
binding of the conformationally sensitive 6D3 and 13C6 
antibodies. Binding of the control 6D8 was unchanged by 
incubation at the higher temperatures. At 50°C or 55°C 
for 24 or 96 h, partial loss of 6D3 binding was observed, 
and after only 10  min at 65 or 75°C, 13C6 binding was 
also lost almost completely. The reason for the more 
rapid loss of 6D3 binding on heating is not yet clear, but 
could be due to partial denaturation of domains of the 
GP as temperature increased.
While incubation at 37°C for as long as 96  h did not 
result in denaturation of GP, the integrity of filaments 
was affected. After incubating a VLP sample for 24 h at 
Table 1 Nanopore analysis of VLP
Sample % FWHM >0.2 ms % Height >2 nA Mean particle size (nm)
Undisrupted 6.7 6.2
Sonicated 0.1 1.9 227
Sonicated and filtered 0.45 µm 0.3 2.1 230
Sonicated and filtered 0.8/0.2 µm 0 0 202
Incubated 37°C 24 h 2.7 11
Incubated 37°C 96 h 2.7 9.1
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37°C, we observed a decreased population of particles 
with long-duration pore transits (Table  1 and Addi-
tional file 1: Figure S2A). This result indicates that longer 
filaments are not stable to extended incubation at 37°C, 
although GP conformation could be maintained even 
when filamentous structure was disrupted.
Having determined the sensitivity of GP in VLP to 
heating, we next evaluated the effects of repeated freeze/
thawing on VLP particle size and the GP conformation. 
The VLP preparation used for these studies was purified 
at USAMRIID and tested after having never been fro-
zen, or having been subjected to 1–3 rounds of freeze/
thawing in PBS or PBS + 5% sucrose. VLP were thawed 
in a 37°C water bath and refrozen on dry ice. No signifi-
cant change in GP conformation (Figure 3c) as a result 
of freeze/thawing was found. Electron microscopy and 
particle sizing measurements also found no significant 
change in size as a result of freeze/thawing (Additional 
file 1: Figure S2B).
Immunopotency testing
Based on our biochemical assessments, we had shown 
that optimized sonication can result in smaller, more 
homogenous VLP that expressed conformationally intact 
GP, while excessive heating of the VLP disrupted the GP 
conformation. To evaluate the relevance of these find-
ings in terms of vaccine efficacy, we vaccinated C57BL/6 
mice with VLP treated under the respective conditions 
and challenged them with ma-EBOV. Based on previous 
studies, we had shown that 10  µg of VLP, based on GP 
content, was the minimum sufficient vaccine dose to reli-
ably achieve 90–100% protection from challenge [24]. We 
therefore used this dose level as our baseline for analysis.
To evaluate the impacts of heating and sonication on 
VLP efficacy, we vaccinated animals with either 10 µg or 
2.5 µg of VLP two times, on the schedule shown in Fig-
ure 4a. As shown in Figure 4 and Additional file 1: Table 
S1 (experiment #1), VLP that were sonicated or heated at 
37°C for 96 h provided comparable protection to filamen-
tous control VLP that were not treated, suggesting that 
these conditions did not impact immunogenicity. In con-
trast, VLP that were heated at 75°C for 15  min did not 
provide protection from challenge, supporting a relation-
ship between GP conformational integrity and immu-
nogenicity. The p-values comparing survival of groups 
treated with control VLP or 75°C heated VLP confirmed 
the deleterious effect of high temperature, while the 
effects of sonication or 37°C incubation were not signifi-
cant. Anti-GP antibody titers in animals vaccinated with 
VLP heated at 75°C were also significantly lower than the 
titers achieved in animals vaccinated with undisrupted 
VLP, sonicated VLP, or VLP heated at 37°C, at both dose 
levels tested (Figure 4).
Figure 3 Accelerated degradation of VLP. a Undisrupted VLP incu-
bated at elevated temperatures for the times indicated and probed 
by antibodies 6D8 (blue), 6D3 (red), or 13C6 (green). The absorbance 
at 408 nm is shown on the y-axis. b Sonicated VLP, same as part A. c 
Undisrupted VLP were subjected to repeated rounds of freeze/thaw-
ing in the presence or absence of 5% sucrose.
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Considering that we had not observed 100% protec-
tion with the 10 µg dose level of sonicated VLP, we chose 
to vaccinate animals with 10 or 20 µg of VLP when com-
paring the impact of filtration on protection (Figure 5 and 
Additional file 1: Table S1, experiment #2). Sonicated VLP 
that were filtered through a 0.45 µm filter displayed compa-
rable immunogenicity to those that were not filtered and to 
undisrupted VLP. VLP that were sonicated and then filtered 
with a 0.8/0.2 μm cutoff had slightly lower efficacy, which 
was statistically significant (p value <0.05) at the 10 µg dose, 
though antibody titers were comparable between all groups.
Nano‑VLP
The results above suggested to us that difficulties in man-
ufacture of full-length filamentous VLP might be over-
come by a reduction in their size, without loss of potency. 
We then developed a procedure for purification of nano-
VLP consisting of a combination of centrifugation, sonica-
tion, glass fiber filtration, and Sartobind S-75 membrane 
negative capture steps; with a final filtration for removal 
of aggregates and bioburden. The SDS-gel electrophore-
sis pattern of the nano-VLP product and a preparation 
made by the sucrose-gradient procedure [3] are shown in 
Figure 4 Impact of heating or sonication on VLP immunogenicity. a Schematic depicting vaccination schedule. b C57BL/6 mice were vaccinated 
two times, with 3 weeks between vaccinations. VLP were untreated, heated at 37°C for 96 h, heated at 75°C for 15 min, or sonicated. Mice were 
challenged 4 weeks after the final vaccination and the percent survival is shown. p-values determined using Fisher’s exact test to compare survival 
of each treatment group at the given dose level to control VLP (“untreated”). c Anti-glycoprotein antibody titers of vaccinated mice measured from 
serum collected 2 weeks after the final vaccination. VLP dose level (10 or 2.5 µg) and treatment (untreated, heating conditions, and sonication 
status) are indicated on the x-axis. P values determined using one-tailed Student’s t test where *p < 0.05, **p < 0.005, ***p < 0.0005.
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Additional file 1: Figure S3. The protein bands appear very 
similar in migration and relative amounts. We also veri-
fied that the nano-VLP preparation possessed appropriate 
GP conformation by ELISA as done above (not shown). 
Measurement of the GP yield by ELISA with antibody 
6D8 gave figures of 1.6–2.0 mg/L of cell culture, in com-
parison with ~1 mg/mL for the sucrose gradient method. 
Both contained 20–30% GP when total protein was meas-
ured by BCA. A final 0.45  μm filtration provided ade-
quate bioburden removal for laboratory usage, yielding a 
product that showed no bacterial growth on plating. Fil-
tration with a 0.8/0.2 μm filter was possible but resulted 
in additional loss of product.
Transmission electron microscopy of the nano-VLP 
with PTA staining showed linear, branched, spherical and 
“6” shaped particles (Figure 6a). Linear filaments were as 
long as 1.5 microns, but most particles were shorter fila-
ments or spheres of ~200 nm diameter. Particle size was 
also examined using a qViro device (Figure 7a). With the 
nano-VLP sample, 7.1% of observed events had a passage 
duration of >0.2  ms. These events may represent pas-
sage of the shorter filaments found in Figure 6a. Results 
from the qViro nanopore analysis appeared to be consist-
ent with the EM data. The nano-VLP were not observed 
to possess lengths of several microns as is commonly 
found in sucrose-gradient purified VLP and authentic 
virions. The mean particle diameter was calculated to be 
230  nm using a spherical bead standard; however, this 
method does not take into account the shape of the fila-
ment fragments. Although some of the fragments of fila-
ments present were longer than the 0.45 micron pore size 
filter used in this preparation, their width was less than 
100 nm.
We tested lyophilization of the nano-VLP as a pos-
sible means to formulate for stable storage. Figure  6b, 
c show electron micrographs of the lyophilized nano-
VLP, after resuspension in water. The filaments retained 
structure after lyophilization, although some shortening 
Figure 5 Impacts of sonication and filtration on VLP immunogenicity. a C57BL/6 mice were vaccinated two times, with 3 weeks between vaccina-
tions, as in Figure 4a. VLP were untreated, sonicated, or sonicated and passed through either a 0.45 µm or 0.8/0.2 µm filter (indicated on x-axis). The 
percent survival is shown. p-values determined using Fisher’s exact test to compare survival of each treatment group at the given dose level to con-
trol VLP (“untreated”). b Anti-glycoprotein antibody titers of vaccinated mice measured from serum collected 2 weeks after the final vaccination. VLP 
dose level (10 or 20 µg) is indicated on the x-axis. P values determined using one-tailed Student’s t test where *p < 0.05, **p < 0.005, ***p < 0.0005.
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of filaments occurred, which was confirmed by nano-
pore analysis (Figure  7a). The calculated mean particle 
diameter of the lyophilized nano-VLP was 217  nm. The 
GP layer coating the lyophilized nano-VLP was visual-
ized by negative staining in Figure 6c, and was detected 
by immunogold-staining with antibody 6D8 (Figure S4). 
Retention of the folded conformation of GP in the nano-
VLP after lyophilization was confirmed using ELISA (Fig-
ure  7b). Lyophilized VLP resuspended readily without 
the appearance of aggregation, and the particles flowed 
easily through the nanopore.
As described above, we observed that the GP of Ebola 
VLP underwent denaturation when heated in liquid sus-
pension to 75°C for 15 min, which was correlated with a 
nearly complete loss of protective capability in the mouse 
model. However, we found that lyophilized nano-VLP 
could be heated in the dry form before resuspension to 
75°C for at least 1 h, with little apparent loss of GP con-
formation as determined by conformational ELISA (Fig-
ure 7b). Electron micrographs of the heated, lyophilized 
nano-VLP (Figure  6d) showed that the filament frag-
ments were relatively unchanged, although increased 
irregularities on the membrane surface were apparent.
Efficacy as a vaccine
The ability of the nano-VLP to confer protection from 
mouse-adapted Ebola challenge was tested in a mouse 
assay. Figure 8a shows results of an experiment in which 
mice were vaccinated with 5  µg doses of various VLP 
preparations [GP content of VLP] in combination with 
10  µg poly-ICLC adjuvant. The VLP preparations that 
were tested are as follow: sucrose-gradient purified VLP, 
Figure 6 Electron micrographs. a Nano-VLP. Bar 2 µm. b Lyophilized nano-VLP, after resuspension. Bar 0.5 µm. c Lyophilized nano-VLP. Bar 0.1 µm. d 
Lyophilized nano-VLP after heating to 75°C for 1 h. Bar 0.1 µm.
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which served as a bridging control to previous studies; 
nano-VLP that were stored frozen; nano-VLP that were 
lyophilized; and lyophilized nano-VLP that had been 
heated in the vial at 75°C for 1 h prior to resuspension. 
All (10/10) animals vaccinated with adjuvant only died 
after challenge with mouse-adapted Ebola virus, while all 
in the VLP-vaccinated groups survived (Figure  8a). The 
anti-GP titers in the VLP-containing groups were uni-
formly high (Figure 8b).
As a more stringent test of immunogenicity, we per-
formed an experiment without the use of adjuvant (Fig-
ure 8c, d). nano-VLP were administered at doses of 5 or 
20 µg GP content (Additional file 1: Table S2). For each 
group, 20  µg conferred better protection than 5  µg. At 
the 20 µg dosage, nano-VLP that had been stored frozen 
yielded 6/10 survival, while lyophilized nano-VLP gave 
10/10 survival and lyophilized/heated VLP gave 9/10. For 
all of these groups except lyophilized nano-VLP at 5 µg, 
survival vs. saline control was statistically significant. 
However, differences in survival between the vaccine 
groups, including the filamentous VLP used in earlier 
studies, were not statistically significant. Anti-GP titers 
also showed a dose response, and titers for the heated, 
lyophilized VLP were significantly higher than titers for 
lyophilized nano-VLP or frozen nano-VLP at the 20  µg 
dose level. The reason for this higher titer is not known.
Discussion
VLP stability and GP conformation
Vaccines that can withstand ambient temperatures for 
extended periods are highly desirable to avoid loss of 
potency if the cold chain is broken. Thermal stability 
studies on VLP indicated that the GP antigen can with-
stand moderately high temperature stress for an extended 
period. Incubation at 55°C for more than 24 h resulted in 
partial loss of conformation, while at 75°C denaturation 
occurred rapidly as measured by ELISA. No significant 
loss of GP conformation was observed with 96 h incuba-
tion at 37°C, however. Loss of conformational integrity in 
the ELISA was correlated to loss of immunopotency in a 
mouse bioassay, demonstrating that the conformational 
ELISA method introduced herein can be used to predict 
rapidly the decreased potency of thermally stressed Ebola 
VLP vaccine samples. Structural studies of neutralizing 
antibodies to Ebola GP support the importance of GP 
conformation in antibody recognition [25].
Only one other study has examined filovirus VLP 
stability systematically, to our knowledge [26]. Those 
authors used biophysical methods on VLP derived from 
a baculovirus expression system, while we employed a 
human cell-based system and developed approaches to 
focus specifically on antigenic integrity. The light scat-
tering and circular dichroism measurements of Hu et al. 
indicated that at neutral pH Ebola VLP’s lost conforma-
tional integrity above 50–60°C. Although the thermal 
transitions were broad, and global properties of the VLP 
were assayed rather than those of GP specifically, those 
results are consistent with ours.
Particle size vs. immunogenicity
Previous studies have found that particles greater 500 nm 
in size are processed more slowly by the immune system 
due to exclusion from direct drainage to lymph nodes 
[11]. This fact might suggest that large filamentous VLP 
would be less immunogenic than smaller VLP. However, 
we found no significant difference in potency between 
the filamentous and sonicated VLP using the mouse vac-
cination model. The roughly 230 nm average size of the 
sonicated VLP was large enough to provide the repeated 
antigen array necessary for strong stimulation of the 
immune response by GP [10]. Passage of the sonicated 
Figure 7 a Nanopore event duration (ordinate) and blockade 
magnitude (abscissa) of non-lyophilized (blue circles) and lyophilized 
(green triangles) nano-VLP. b ELISA to probe the conformational integ-
rity of GP in nano-VLP that were not lyophilized, lyophilized, and lyo-
philized and heated to 75°C for 1 h. Blue bars linear epitope antibody 
6D8, red bars conformational antibody 6D3, green bars conformational 
antibody 13C6.
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VLP through a 0.45  µm filter did not appear to affect 
potency, but passage through a 0.8/0.2 µm filter resulted 
in a lower survival rate after challenge. However, a statis-
tically significant difference in potency of the more strin-
gently filtered VLP was observed only at the 10 µg dose 
(Additional file 1: Table S1).
To the extent that the mouse model is predictive, our 
results indicate that the presence of intact filaments is 
not essential to a VLP vaccine. The finding that reduc-
tion of particle size by sonication did not greatly change 
immunogenicity may be due at least in part to disrup-
tion of longer VLP filaments in vivo. We observed that 
extended incubation at 37°C resulted in shortening of 
filaments, as determined by nanopore sizing measure-
ments. This suggests that VLP filaments will breakdown 
into pieces after injection into the body of an animal, 
with the result being that the large initial size of the VLP 
may not be an impediment to access to the lymphatic 
system.
Nano‑VLP and progress in vaccine development
We have described a new process for purification of a 
filovirus VLP vaccine that is more rapid and easily scaled 
for manufacturing than the previous sucrose gradient-
based method. The size of the nano-VLP was smaller 
than that of complete Ebola virions, with spherical parti-
cles of roughly 230 nm diameter, and filaments of around 
500  nm length. Nevertheless, the Ebola nano-VLP 
remained larger than typical viruses and GP in the native 
conformation was present on the surface of the nano-
VLP. Reduction in size of the VLP facilitated their puri-
fication by membrane chromatography, which is more 
easily adapted to large-scale production than a sucrose 
gradient method. The resulting product was also more 
uniform in size, although differences in morphology 
between spherical and filamentous fragments remained. 
Further advancements will be necessary to bring our lab-
oratory-scale method to cGMP scale and meet all FDA 
criteria for product licensure.
Figure 8 a C57BL/6 mice were vaccinated two times, with 3 weeks between vaccinations, as in Figure 4a. Dose level of VLP or nano-VLP (nVLP) 
was 5 µg, based on GP content, and dose level of the adjuvant poly-ICLC was 10 µg. Time to death in days, expressed as percentage survival in each 
group. All animals except those in the adjuvant-only poly-ICLC control group survived. b Anti-glycoprotein titers of mice from A inoculated with 
adjuvant alone, or adjuvant plus sucrose-gradient control VLP, frozen nVLP, lyophilized nVLP, and lyophilized nVLP heated to 75°C for 1 h. c Time to 
death in days, expressed as percentage survival in each group of mice vaccinated with 5 or 20 µg nVLP doses, without adjuvant. The experiment 
compares results for nVLP stored frozen, lyophilized nVLP, lyophilized and heated nVLP, and a control of sucrose-gradient purified VLP. p-values 
determined using Fisher’s exact test to compare survival of each treatment group vs. saline. d Anti-glycoprotein titers of mice from c. P values deter-
mined using one-tailed Student’s t-test where *p < 0.05, **p < 0.005, ***p < 0.0005. “Lyoph” indicates lyophilized material.
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We have also presented assays for in  vitro testing of 
GP conformational integrity in the context of VLP, the 
presence and relative population of filaments, and the 
concentration of particles in filtered VLP samples. The 
observed correlation of the conformational ELISA with 
the mouse immunopotency assay may allow its use in the 
future as a more rapid quality-control assay for the VLP 
and other types of Ebola vaccines, while the concentra-
tion of particles can be measured using the rate of events 
observed during flow through a nanopore.
Our results indicated that the lyophilized nano-VLP 
preparation was highly thermostable, but further studies 
will be needed to determine if long-term storage of the 
lyophilized formulation without refrigeration is possible. 
Elimination of a cold chain requirement would decrease 
costs associated with the vaccine and greatly ease distri-
bution to locales without reliable electricity, especially 
important for a tropical disease [27].
Conclusions
We developed a procedure to reduce the size of filovi-
rus VLP, which permitted us to purify “nano-VLP” using 
chromatography and filtration. We found that Ebola VLP 
can be reduced to a more uniform and easily manipulable 
size range of roughly 230  nm diameter, while retaining 
GP conformational integrity and the antigenic effective-
ness of the vaccine. Additionally, the nano-VLP can be 
lyophilized without loss of GP and VLP structure and 
immunogenicity. Lyophilized nano-VLP have greatly 
enhanced thermostability, suggesting that the creation of 
an Ebola VLP vaccine without a cold chain requirement 
is possible.
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